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Summary 
Background 
Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for 
patients in hospital. We aimed to establish whether short term routine use of antimicrobial 
catheters reduced risk of CAUTI.  
 
Methods 
This was a three parallel group superiority trial whereby silver alloy-coated catheters and 
nitrofurazone-impregnated catheters were compared with the control of standard 
polytetrafluoroethylene-coated catheters. Adults requiring short-term catheterisation were 
recruited in 24 UK hospitals and randomised using remote computer allocation. Patients 
undergoing unplanned catheterisation were also randomised and consent for participation 
sought retrospectively. Participants and trial staff were not blinded. Data were collected by 
trial staff and by patient questionnaire for six weeks after randomisation. The primary 
outcome was incidence of symptomatic CAUTI for which an antibiotic was prescribed. We 
hypothesised that a 3.3% absolute reduction in CAUTI was sufficient benefit for routine use 
of antimicrobial catheters to be considered.  
 
Findings 
Of 7102 randomised participants, 708 (10%) were either not catheterised, did not confirm 
consent or withdrew. Of 6394 included in the analysis, 2097 were allocated to silver alloy, 
2153 to nitrofurazone, and 2144 to control. Compared to control, the difference in incidence 
of CAUTI up to six weeks post-randomisation (95% confidence interval) was -0.1% (-2.4 to 
2.2) for silver alloy, and -2.1% (-4.2 to 0.1) for nitrofurazone catheters. The nitrofurazone 
group had higher catheter-related discomfort. 
 
Interpretation 
Silver alloy-coated catheters were not effective at reducing symptomatic CAUTI. The 
reduction in CAUTI associated with nitrofurazone-impregnated catheters was less than that 
considered clinically important and we therefore conclude that the trial has shown no 
evidence to support their routine use.  
 
Trial registration: 
ISRCTN75198618  
 
Funding: 
The trial was fully funded by the Heath Technology Assessment Programme of the United 
Kingdom Government National Institute for Health Research (ref: 05/46/01) 
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Introduction 
Urinary tract infection (UTI) associated with indwelling catheters that drain urine during and 
after surgery or critical illness is the second most common cause of hospital-acquired 
infection worldwide with a conservative estimate of 145,000 adults affected in the United 
States in 20101,2,3 and 47% of newly catheterised patients in the Philippines4. Catheter-
associated UTI (CAUTI) causes avoidable patient morbidity and increased healthcare costs 
in high-income and developing countries5,6. Implementation of evidence-based prevention 
strategies including avoidance of catheter use, aseptic catheter insertion, and minimisation 
of duration of catheterisation7,8 have been associated with a 50% reduction in CAUTI in 
hospitals3,9. Another option is to use catheters with antimicrobial coatings to delay bacterial 
colonisation; two widely available examples are a silver alloy-coated latex catheter and a 
nitrofurazone-impregnated silicone catheter, which both inhibit urinary pathogens10. A 
Cochrane review11 found that although these devices may reduce bacterial contamination of 
urine, their usefulness in combating symptomatic CAUTI and avoiding need for antibiotic 
treatment was uncertain. Recent guidance called for more evidence of effectiveness prior to 
routine implementation and emphasised the need to focus on clinical outcomes such as 
symptomatic UTI8. We report a pragmatic randomised controlled trial commissioned by the 
United Kingdom (UK) National Institute for Health Research (NIHR) which aimed to establish 
whether antimicrobial catheters reduced risk of clinical CAUTI in short term (≤ 14 days) use 
compared to a standard catheter. The primary objective was to determine the comparative 
effectiveness of a silver alloy-coated catheter and a nitrofurazone-impregnated catheter 
against a standard polytetrafluoroethylene (PTFE) catheter in reducing incidence of 
symptomatic CAUTI treated with antibiotics. Secondary objectives were to assess 
comparative effectiveness in reducing microbiologically-proven CAUTI and rates of 
bacteriuria. We intended to provide these data to clinicians, patients and healthcare policy 
makers to inform them of the merit of these devices in the setting of routine hospital care. 
 
Methods 
Participants 
Between July 2007 and October 2010 adults undergoing urethral catheterisation for an 
anticipated duration of up to 14 days were identified from 24 UK National Health Service 
(NHS) hospitals providing surgical care across various specialties (Web Extra Table i). 
Participants requiring planned catheterisation as part of standard care were identified by 
local researchers. Instances of unplanned catheterisation with an anticipated short duration 
were identified by ward staff. We used wide eligibility criteria including people with diabetes 
and those treated with immune suppressive agents. Exclusion criteria included symptomatic 
UTI at baseline, having a urological procedure in the last seven days, and allergy to catheter 
materials. Participants gave written, informed consent before randomisation except those 
having unplanned catheterisation who were randomised and then invited to consent when 
sufficiently recovered; if they declined they were excluded. The trial was approved by a UK 
NHS Research Ethics Committee and overseen by Trial Steering and Data Monitoring 
Committees.  
 
Interventions 
Participants were allocated using simple randomisation in a 1:1:1 ratio to one of the two 
experimental interventions; a silver alloy-coated latex catheter, and a nitrofurazone-
impregnated silicone catheter, or to the control of standard PTFE-coated latex catheter. 
Randomisation was implemented using a computer generated system that was concealed 
and remote from the users via a constantly available automated telephone service or secure 
website. Compliance with the allocated intervention was recorded. Participants, clinicians 
and the trial team were not blinded to the allocated intervention due to the distinctive 
appearances of each catheter. Where the period of catheterisation was unexpectedly longer 
than 14 days trial data were collected as if the catheter had been removed on day 14. 
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Outcomes 
The primary outcome was the incidence of symptomatic CAUTI, defined as the presence of 
participant-reported UTI symptoms and clinician prescription of antibiotic for a UTI at any 
time up to six weeks after randomisation. Secondary outcomes included incidence of 
microbiologically-confirmed symptomatic CAUTI, defined as those with the primary outcome 
and a positive urine culture; incidence of bacteriuria at up to three days after catheter 
removal; changes in health-related quality of life during the six week period of trial 
participation; and urethral discomfort related to catheterisation. 
 
Study Procedures 
Baseline data came from clinical records and self-completed participant questionnaire. 
Outcome data were collected from clinical records by local trial staff during hospitalisation 
and by self-completed participant questionnaire or diary at three days following catheter 
removal, one and two weeks after catheter removal and at six weeks after randomisation. 
Participant questionnaires included symptoms of UTI, catheter discomfort (categorised as 
mild, moderate, or severe), antibiotic use, and the generic health-related quality of life 
measure; EQ-5D©12. Participant report of an episode of CAUTI after leaving hospital was 
verified by contacting the primary care physician to confirm prescription of an antibiotic for 
UTI. Mid-stream voided urine samples, or alternatively samples of urine taken directly from 
the catheter were collected at baseline, at up to three days after catheter removal and, if 
feasible, at the time of CAUTI and were analysed according to microbiology laboratory 
protocols in UK NHS hospitals with a positive result defined as bacterial counts ≥ 104 cfu/mL 
of no more than two microorganisms. 
 
Statistical analysis 
Considering the degree of benefit required to change practice we specified a 3.3% absolute 
reduction based on estimated incidence in the control group of 11% (30% relative reduction; 
odds ratio 0.67). For 90% power and at the 2.5% significance level to account for the two 
comparisons, and allowing for an attrition rate of 15%, required 2,345 participants for each 
arm; 7,035 participants in total. Two comparisons of equal importance were tested in the 
trial; silver alloy versus PTFE catheters, and nitrofurazone versus PTFE catheters. Estimates 
of UTI outcomes were analysed using logistic regression and summarised as absolute 
percentage risk differences and odds ratios, both with 95% confidence intervals (CI) 
calculated as 97.5% confidence intervals to adjust for the two comparisons. All included 
participants were analysed in their allocated group regardless of the catheter received 
according to intention to treat principles and were assumed to have not suffered a 
symptomatic CAUTI unless fulfilling primary outcome criteria. Outcomes were reported 
unadjusted and using adjusted models corrected for age, gender, co-morbidity, indication for 
catheterisation and antibiotic use prior to catheterisation. Sensitivity analysis was carried out 
using recruiting hospital as a random effect. The influence of factors known to modify CAUTI 
risk on the observed effectiveness of the experimental catheters relative to control was 
examined by tests for interaction at the 1% significance level given their exploratory nature. 
A post-hoc effect modification sensitivity analysis was carried out to explore any potential 
effects of duration of catheterisation on observed effectiveness. All subgroup and treatment 
effect modification analyses were carried out using the same generalised linear modelling 
framework as the main analyses. Responses to the EQ-5D© were plotted as mean and 
standard deviation at 3 days and 1 and 2 weeks post catheter removal, and at 6 weeks post 
randomisation and changes assessed by calculating the area under the curve. Sensitivity to 
missing data was explored using the missing at random assumption but no imputation was 
performed. All outcomes related to symptoms and catheter associated discomfort were 
analysed using ordered logit models suitable for ordinal outcome data. Analyses were 
carried out using SAS 9.2 (SAS Institute Inc. 2010. SAS/GRAPH® 9.2. Cary, NC USA: SAS 
Institute Inc.) and Stata 11 (StataCorp. 2009. Stata Statistical Software: Release 11. College 
Station, TX USA: StataCorp LP.). 
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Trial registration 
Registration number ISRCTN75198618. The trial protocol13 was peer-reviewed by The 
Lancet. 
 
Role of the funding source 
The funder had no role in design, collection, analysis, or interpretation of data, or writing of 
the report. RP, TL, JN’D, CB, MK, GMcP, GM and LV had full access to data collected for 
the trial. All authors agreed to submit for publication. 
 
Results 
We randomised 7,102 patients of whom 430 either did not provide retrospective consent or 
withdrew their consent prior to catheterisation and were excluded. A further 278 randomised 
and consenting individuals became ineligible predominantly because they did not undergo 
urethral catheterisation due to changed clinical care decisions. Data from 6,394 (90%) 
randomised participants, including 520 (8%) who gave retrospective consent following 
unplanned catheterisation, were included in the intention to treat analysis. A total of 272 
(4%) participants included in the analysis did not receive the allocated catheter because 
clinical staff substituted an alternative catheter instead (Figure 1). Reason for catheterisation 
was recorded for 6296 participants of whom 5966 (95%) required peri-operative monitoring 
of urine output and 277 (5%) had urinary retention. The proportion of participants under the 
care of different specialities recruiting to the trial was balanced across the three groups (Web 
Extra Table ii). Baseline characteristics (Table 1) and response rates to postal questionnaire 
(Figure 1) were similar across groups. Primary outcome data for the intention-to-treat 
analysis was obtained for all but one non-responder in whom it was assumed that no CAUTI 
occurred. 
 
Incidence of symptomatic CAUTI up to six weeks post-randomisation was 12.5% amongst 
participants randomised to silver alloy catheter, and 10.6% in those randomised to 
nitrofurazone catheter, compared to 12.6% for the PTFE control giving absolute risk 
differences (95% CI) of -0.1% (-2.4 to 2.2) and -2.1% (-4.2 to 0.1) respectively. The odds 
ratio (95% CI) for symptomatic CAUTI compared to control was 0.99 (0.81 to 1.22; p= 0.92) 
for use of the silver alloy catheter, and 0.82 (0.66 to 1.01; p= 0.037) for use of the 
nitrofurazone catheter (Table 2). A sensitivity analysis incorporating recruiting hospital gave 
practically identical results (Table 3). There were no reported admissions to intensive care 
unit or deaths attributed to CAUTI. There was no difference between groups in duration of 
catheterisation and hospitalisation (Table 1). There was no interaction between observed 
effectiveness of the antimicrobial catheters and presence of risk factors for CAUTI (Figure 
2a-c). In particular the modelled interaction between catheter duration and both the silver 
alloy versus control and the nitrofurazone versus control comparisons was not significant (p 
= 0.83 and p = 0.19 respectively). The time of occurrence of CAUTI relative to catheter 
removal is shown in Table 4. The nitrofurazone catheter used in the trial was associated with 
a lower incidence of microbiologically-proven symptomatic CAUTI (p = 0.02) and a lower 
rate of bacteriuria (p = 0.001), but also greater participant-reported discomfort during use 
and at removal (Table 2). There were no statistically significant differences in health status 
between trial groups over the period of observation (Table 5).  
 
Discussion 
We sought to determine whether short-term use of either of two available antimicrobial 
catheters was clinically effective in reducing CAUTI compared to the PTFE control. 
Interpretation of the findings depends on the level of benefit thought sufficient to justify 
changes in practice. From the clinician perspective and taking into account previously 
reported effect sizes15,16,17, we considered that use of an antimicrobial catheter would be 
worthwhile if about one in 30 people avoided suffering a CAUTI (3.3% absolute reduction) 
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and powered our trial accordingly. It is possible that others, such as patients needing short-
term catheterisation or the healthcare funders with a finite budget, would have required 
lesser or greater degrees of benefit. Consideration from different perspectives of trial 
estimates of clinical effectiveness with their associated uncertainties will determine how our 
results are interpreted. 
 
Silver alloy-coated catheters 
Our best estimate of the effectiveness of the silver alloy catheter compared with control was 
close to no difference. The results suggest that 1,000 people would need to receive a silver 
alloy catheter to prevent one CAUTI, with the true effect lying between one infection 
prevented in 42 people and one infection caused in 45 people. As the CI did not include the 
pre-stated effect size but did include zero we conclude that the silver alloy catheter is not 
effective. Our conclusion is important since hospitals in the USA and UK have implemented 
silver alloy-coated catheters for routine short-term use as part of CAUTI prevention17,18,19. 
This followed a meta-analysis of previous trials showing a relative risk (95% CI) of 0.54 
(0.43-0.67) for bacteriuria11, a finding that did not change substantially on re-analysis taking 
into account possible bias20. We felt that bacteriuria did not map closely to clinical diagnosis 
of UTI and therefore used a primary patient-reported UTI outcome backed by clinician action 
of antibiotic prescription without requirement for microbiological proof, assessed for at least 
four weeks after catheter removal. This was to better reflect clinical care and patient 
experience with an adequate observation period to capture relevant events, and to fulfil 
research priorities set out in international public health policy guidelines7,21,22. Our secondary 
outcomes of microbiologically-proven symptomatic CAUTI and bacteriuria at up to three 
days after catheter removal align better with previous trials but again showed the silver alloy 
catheter to be ineffective. The early change in practice made by some hospitals was based 
on limited evidence of effectiveness primarily from underpowered studies; the contrast 
between the finding of no difference from a robustly designed, large, multi-centre pragmatic 
trial, and initial promising findings from smaller explanatory trials has been observed 
previously23. 
 
Nitrofurazone-impregnated catheter 
The best estimate of effectiveness for the nitrofurazone catheter is that they would prevent 
one symptomatic CAUTI in every 48 people catheterised, but that the true effect could lie 
between one in 24 people and no protective effect at all. This estimate was less than the 
effect size sought and the confidence interval included zero so we conclude that routine use 
of nitrofurazone catheters for short term catheterisation did not give the degree of benefit 
that we consider to be clinically relevant. The potential increased discomfort experienced by 
about one in 9 people, adding to the distress of an already intimate invasive intervention 
should also be noted. The estimate of effectiveness seen in our trial was smaller than that 
from meta-analyses of previous trials8,11 and in particular contrasts with an earlier report of a 
relative risk (95% CI) for antibiotic-treated CAUTI recorded as a secondary outcome of 0.27 
(0.10 to 0.69) in favour of nitrofurazone catheters24. Use of bacteriuria as a primary outcome 
and missing data for the secondary outcomes in this report limits useful comparison with our 
results. The contrasting lack of effectiveness seen in our trial may reflect wider eligibility 
criteria, shorter catheter duration and pragmatic design. Our results for microbiological 
CAUTI and bacteriuria were suggestive of a relevant antimicrobial effect, but this might be 
offset by public health concerns regarding widespread antimicrobial use. Current evidence 
suggests that nitrofuran-based antimicrobials are less prone to development of bacterial 
resistance25 although this was not monitored in our trial. The silicone material of manufacture 
may have contributed to greater antimicrobial effect compared to latex control, but we did not 
explore this since we aimed to test the effectiveness of the device as an available 
technology and accordingly rejected the option of including a standard silicone catheter as a 
second control arm. 
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Strengths and limitations of the trial 
This trial was pragmatically designed to evaluate clinical effectiveness of two widely 
available antimicrobial catheters. We sought to resolve uncertainty concerning benefit of 
antimicrobial catheters for short term use, focusing on the clinically relevant outcome of 
symptomatic UTI treated with antibiotics rather than microbiologically defined bacteriuria8. 
We considered that our chosen primary outcome would be measurable and represent a 
clinically important event reflecting patient experience. This definition and our successful 
attribution of the outcome across the trial population allowed strong and practically useful 
conclusions to be drawn concerning the clinical effectiveness of antimicrobial catheters. We 
also adopted a pragmatic approach to recruitment ensuring participants reflected the broad 
spectrum of patients needing short term catheterisation in hospital, with particular focus on 
those admitted for elective surgery, the population most often requiring this intervention, 
meaning that the results can be readily generalised. The wide spectrum of hospital type, 
specialities, and surgical procedures was protective against selection bias but we did not 
recruit patients admitted directly to intensive care units and the number of eligible patients 
identified and recruited from acute medical wards was small.  
 
The trial was powered at 90% to detect what we considered to be a clinically meaningful 
benefit from routine use of the antimicrobial catheters tested. For both comparisons the 
central estimate was less than the effect size sought and the confidence interval included 
zero. The results therefore allow a firm conclusion to be made that there is no statistically 
significant difference between either the silver alloy or the nitrofurazone catheters and 
control. Assuming that our hypothesised effect size of 3.3% and CAUTI incidence with a 
standard catheter of 11% were correct there remains an approximate 10% chance of a type 
II error causing us to wrongly conclude that they are ineffective. It is possible that others may 
have considered a lesser absolute difference in CAUTI risk to be worth exploring and 
powered the study accordingly. We are however confident that the 3.3% difference we set 
out to identify is a plausible estimate of the minimum benefit required to change routine 
practice. 
 
To minimise misclassification of participants’ self-report of UTI we successfully resolved any 
missing data and confirmed CAUTI through verification of clinician prescription of antibiotic. 
Given the size of the trial and available resources we could not independently verify that 
participants reporting no CAUTI after discharge from hospital had not received a prescription 
of antibiotic for UTI. We consider it unlikely that any misclassification of absence of CAUTI 
could be differential across trial groups since decisions by participants not to report 
symptoms and treatment decisions by primary care clinicians would not be influenced by the 
type of catheter used. It is possible that some episodes of community-acquired UTI were 
captured, particular for participants with short catheter duration. However recent 
catheterisation would remain a risk factor and there was no interaction between duration and 
effectiveness. Telephone and internet-based trial entry with computer-generated simple 
randomisation minimised risk of allocation bias. Post-randomisation withdrawals were 
primarily due to patients not being catheterised and refusal to participate after unplanned 
catheterisation with no relation to the catheter allocated. We could not mask the allocated 
catheter, but clinical staff who inserted the catheter were unlikely to be involved in decisions 
regarding timing of removal or antibiotic prescription for CAUTI.  
 
We used ≥ 104 cfu/mL as the threshold for a positive urine culture since this was consistently 
reported by participating hospital laboratories. This may have resulted in higher absolute 
rates for microbiologically-driven outcomes compared to the more usual ≥ 105 cfu/mL 
criterion but we have no evidence that it resulted in any bias to our comparisons. We did not 
monitor use of other CAUTI prevention actions in participating hospitals, but found no 
evidence for interaction between hospital and comparative effectiveness. This provides 
some reassurance that any possible differences between institutions or individual clinicians 
in terms of diagnosis of clinical CAUTI or criteria used to initiate antibiotic treatment did not 
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impact on our primary outcome. It is possible that catheter duration experienced by most 
participants was too short to allow the anti-microbial effect of the tested catheters to become 
apparent. The study was designed to align with routine hospital practice and it is unlikely in 
this setting that patients anticipated as requiring differing short periods of catheterisation 
could be separated and receive different catheters. Furthermore we found no significant 
interaction between catheter duration and differences in incidence of CAUTI. The median 
duration seen in our trial is representative of current practice 26. 
 
Implications of trial findings for clinical practice and research 
Our results give no support for the routine use of silver alloy-coated catheters. The 
nitrofurazone catheter was not effective according to our pre-stated criterion and we would 
therefore regard our trial as showing no evidence to justify its use. However some, 
particularly patients requiring short term catheterisation, or providers seeking to reduce 
healthcare-acquired infection rates, may judge that a lesser degree of benefit might be 
sufficient and be encouraged by our finding of statistical significance for secondary 
microbiological outcomes. We caution against such alternative conclusions since they are 
not supported by the primary trial result. Hospitals will need to carefully consider the lack of 
effectiveness of the tested catheters taking into account differences between the UK NHS 
and their own healthcare system. Those who have already implemented use of silver alloy 
catheters may have an opportunity to reallocate resources without loss of benefit, while 
organisations planning their implementation may wish to reconsider. Overall it would seem 
appropriate for patients, clinicians and healthcare providers to persist with simple strategies 
to prevent CAUTI and await any adjustment of guidance on CAUTI prevention in the light of 
our results before making a decision1,7,22,27. 
 
Word count: 
Abstract 263, Text 3,385 
 
Panel: Research in Context 
 
Systematic review 
This trial was commissioned because a Cochrane Review published in 2004 and updated in 
2008 found that although the summarised evidence from published randomised trials 
suggested that antimicrobial catheters reduced the rate of microbiological bacteriuria, there 
was no evidence for an associated reduction in patient morbidity related to symptomatic 
catheter-associated urinary tract infection (CAUTI). This was confirmed by a further 
systematic review and re-appraisal of the Cochrane meta-analysis published by the United 
States Centres for Disease Control and Prevention (CDC) in 2009 which emphasised the 
need for large pragmatic trials using symptomatic CAUTI as the primary outcome. 
 
Interpretation 
The pragmatic design and large sample size of this trial, and use of primary outcomes 
combining patient, clinician, and healthcare provider perspectives, gives clear information 
regarding the relative benefit of two widely available antimicrobial catheters. Our finding that 
neither the silver alloy-coated catheter nor the nitrofurazone-impregnated catheter reached 
our pre-stated minimum level of clinical effectiveness will allow better decisions to be made 
concerning use of these devices in healthcare. 
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Table 1: Baseline and other participant characteristics  
Cell values are n (%) unless otherwise stated.  PTFE = polytetrafluoroethylene, SD = standard 
deviation, MSU = mid-stream specimen of urine, CSU = catheter specimen of urine, cfu = colony-
forming unit. *Immune suppression was defined as a participant being currently treated with an 
immunosuppressive therapy including corticosteroids, methotrexate, and chemotherapeutic agents. 
  Silver alloy  Nitrofurazone PTFE control 
  N =   2097 N =   2153 N =   2144 
Age in years:  mean [SD] 
 
59 [16] 59 [16] 59 [16] 
Female 
 
1319 (63) 1333 (62) 1325 (62) 
Unplanned catheterisation 
 
94 (5) 94 (5) 89 (4) 
Co-morbidity associated with 
increased CAUTI risk – valid N 
2084 2138 2136 
Urological condition 196 (9) 214 (10) 214 (10) 
Diabetes 207 (10) 197 (9) 216 (10) 
Immune suppression* 144 (7) 135 (6) 151 (7) 
Antibiotics given within seven days 
prior to randomisation 
 
370 (18) 396 (18) 385 (18) 
Prophylactic antibiotics given prior to 
surgical procedure 
 
1529 (73) 1537 (71) 1547 (72) 
Antibiotics given during period of 
catheterisation for reasons other than 
CAUTI 
 
533(25) 511 (24) 474 (22) 
Antibiotics given after catheter removal 
for reasons other than CAUTI 
 
193 (9) 178 (8) 204 (10) 
Baseline urine sample - valid N 
 
2002 2074 2057 
   MSU 1709 (85) 1735 (84) 1721 (84) 
   CSU 293 (15) 339 (16) 336 (16) 
Baseline number of cfu/mL - valid N 
 
1998 2071 2054 
  No reported growth 1830 (92) 1923 (93) 1901 (93) 
  ≥ 104 168 (8) 148 (7) 153 (7) 
Median duration of catheterisation in 
days (interquartile range) 
 
2 (1-3) 2 (1-3) 2 (1-3) 
Prolonged catheterisation 
> 14 days 
 
73 (4) 79 (4) 67 (3) 
Median duration of hospitalisation in 
days (interquartile range) 
 
6 (3-8) 6 (3-9) 6 (3-9) 
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Table 2: Primary and other trial outcomes 
 
Primary outcome: Symptomatic antibiotic-
treated UTI within six weeks of randomisation 
Silver alloy Nitrofurazone 
PTFE 
control 
N = 2097 N = 2153 N = 2144 
Incidence n (%) 263 (12.5) 228 (10.6) 271 (12.6) 
Absolute percentage risk difference (95% CI) 
compared to PTFE control 
-0.1 (-2.4 to 2.2) -2.1 (-4.2 to 0.1) 
 
Odds Ratio  (95%CI); [p-value]·         unadjusted 0.99 (0.81 to 1.22); [0.92] 0.82 (0.66 to1.01); [0.037]  
Odds Ratio  (95%CI); [p-value]·         adjusted 0.96 (0.78 to 1.19); [0.69] 0.81 (0.65 to 1.01); [0.031]  
 
Secondary outcome: Symptomatic UTI treated 
with antibiotics any time up to six weeks post-
randomisation and associated with positive 
urine culture (≥10
4
 cfu/mL) N = 2097 N = 2153 N = 2144 
Incidence n (%) 105 (5.0) 69 (3.2) 99 (4.6) 
Absolute percentage risk difference (95% CI) 
compared to PTFE control 
0.4 (-1.2 to 1.9)  -1.4 (-2.7 to -0.1) 
 
Odds Ratio  (95%CI); [p-value]·         unadjusted 1.08 (0.78 to 1.52); [0.55] 0.68 (0.48 to 0.99); [0.017]  
Odds Ratio  (95%CI); [p-value]·         adjusted 1.09 (0.78 to 1.51); [0.58] 0.68 (0.47 to 0.98); [0.019]   
 
Secondary outcome: Bacteriuria (symptomatic 
and asymptomatic) detected by urine culture at 
anytime up to three days after catheter removal 
(≥10
4
 cfu/mL) N = 1785 N = 1846 N = 1839 
Incidence n (%) 310 (17.4) 249 (13.5) 321 (17.5) 
Absolute percentage risk difference (95% CI) 
compared to PTFE control 
-0.1 (-3.2 to2.8) -4.0 (-6.7 to –1.2) 
 
Odds Ratio  (95%CI); [p-value]·         unadjusted 
 
0.99 (0.82 to 1.21); [0.94]  
 
0.74 (0.60 to 0.91); [0.001]   
Odds Ratio  (95%CI); [p-value]·         adjusted 
 
0.99 (0.81 to 1.21); [0.89]  
 
0.73 (0.59 to 0.90); [0.001]   
 
Secondary outcome: Self-reported participant 
discomfort ratings with catheter in place N = 1829 N = 1879 N = 1889 
Incidence of any discomfort n (%) 322 (17.6) 496 (26.4) 396 (21) 
Absolute percentage risk differences (95% CI) for 
experiencing grades of discomfort compared to 
PTFE control 
-3.4 (-6.4 to -0.4) 5.4 (2.2 to 8.7) 
 
Odds ratio of experiencing discomfort (95% CI): 0.81 (0.67 to 0.98) 1.35 (1.13 to 1.62)  
 
Secondary outcome: Self-reported participant 
discomfort ratings for catheter removal N = 1817 N = 1867 N = 1881 
Incidence of any discomfort n (%) 521 (28.7) 707 (38.9) 499 (26.5) 
Absolute percentage risk difference (95% CI) for 
experiencing grades of discomfort compared to 
PTFE control 
2.2 (-1.3 to 5.6) 11.3  (7.8 to 14.9) 
 
Odds ratio of experiencing discomfort (95% CI) 1.11 (0.94 to 1.31) 1.69  (1.44 to 1.97)  
 
 
 
 
Adjusted models corrected for age, gender, co-morbidity, indication for catheterisation and antibiotic 
use prior to catheterisation. Analysis by intention-to-treat. PTFE = polytetrafluoroethylene, UTI = 
urinary tract infection, CI = confidence interval. Absolute risk difference derived from logistic 
regression models using delta method. 
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Table 3: Sensitivity analysis of interaction between recruiting hospital and primary 
effectiveness outcome [odds ratio (95% confidence interval) for comparative 
incidence of symptomatic CAUTI between experimental and control] 
 
Comparison 
 
 
Silver Alloy vs. PTFE control 
 
 Fixed Effects 
 
Random Effects 
 unadjusted  
 
0.99 (0.81 to 1.22); [0.92]  1.00; (0.84, 1.22); [0.88]  
 adjusted  
 
0.96 (0.78 to 1.19); [0.69]  0.99; (0.81, 1.20); [0.88] 
Nitrofurazone vs. PTFE control 
 
 Fixed Effects 
 
Random Effects 
 unadjusted  
 
0.82 (0.66 to 1.01); [0.037]  0.83 (0.69, 1.02); [0.039]  
 adjusted  
 
0.81 (0.65 to 1.01); [0.031]  0.83 (0.68, 1.02) ;[0.045]  
Cell values are odds ratio (95% confidence interval) [p value]. CAUTI = catheter-associated urinary 
tract infection; PTFE = polytetrafluoroethylene. 
 
 16 
 
Table 4: Timing of report of CAUTI relative to catheterisation status 
 
 
Silver alloy 
N=2097 
Nitrofurazone 
N=2153 
PTFE control 
N=2144 
No CAUTI n 1834 1925 1873 
% 87 89 87 
CAUTI during catheterisation n 34 28 33 
% 2 1 2 
CAUTI reported prior to completion of 
week one diary 
n 99 77 92 
% 5 4 4 
CAUTI reported in week one or week two 
diary or on six week questionnaire 
n 127 122 144 
% 6 6 7 
Missing* n 3 1 2 
CAUTI = Catheter-associated urinary tract infection. *Participants whose catheterisation status could 
not be ascertained. 
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Table 5: Participant health state measured by responses to the EQ-5D© questionnaire 
at study time-points for each trial arm* 
 
Follow-up time point 
Silver alloy 
N =   2097 
Nitrofurazone 
N =   2153 
PTFE control 
N =   2144 
Baseline prior to randomisation 
 
2076,    0.72 (0.29) 2127,   0.72 (0.29)          2123,    0.72 (0.3) 
3 days after catheter removal 
 
1801,    0.58 (0.28) 1860,   0.59 (0.27) 1871,    0.59 (0.27) 
1 week after catheter removal 
 
1308,    0.60 (0.29) 1363,   0.62 (0.27) 1366,    0.61 (0.27) 
2 weeks after catheter removal 
 
1328,    0.69 (0.27) 1405,   0.70 (0.26) 1398,    0.70 (0.25) 
6 weeks after randomisation 
 
1665,    0.78 (0.24) 1705,   0.78 (0.24) 1721,    0.80 (0.23) 
Cell contents are valid n, mean (SD), higher score represents better health status. SD = standard 
deviation. 
* The EQ-5D, a generic health status measurement tool, divides health status into 5 dimensions 
(mobility, self care, usual activities, pain/comfort and anxiety /depression)
12,
 Each of these dimensions 
has three levels, therefore, there are 243 possible health states. The utility scores were used to 
calculate QALYs by multiplying the time spent in each health state by the utility score for that state 
14
. 
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Figure 1: Progress of participants through the trial  
 
* Generally participants underwent catheterisation in the operating suite.  In 272 (4.3%) of 
cases an alternative catheter to that allocated by randomisation was inserted mainly due to 
error by clinical staff. The numbers of participants dying, declining further follow up or not 
responding are cumulative in direction of participant flow. The questionnaires and diaries 
were completed at three days and at one and two weeks after catheter removal and finally at 
six weeks after the day of randomisation.  
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Figure 2a: Forest plots of subgroup analyses; catheter-associated urinary tract 
infection at any point up to six weeks post randomisation for silver alloy versus 
polytetrafluoroethylene control comparison  
 
 
OR = odds ratio, CI = confidence interval 
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Figure 3b: Forest plots of subgroup analyses. Catheter-associated urinary tract 
infection at any time up to six weeks post randomisation for nitrofurazone versus 
polytetrafluoroethylene control comparison   
 
 
 
OR = odds ratio, CI = confidence interval. 
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Figure 3c: Graphical plot of incidence of catheter associated urinary tract infection at 
up to six weeks following randomisation against duration of catheterisation for trial 
groups showing both the observed incidence and that predicted by the statistical 
model 
 
 
Accompanying data table for Figure 3c 
Day 1 2 3 4 5 6 7 8 9 10 
Silver alloy 89/666 
(13.3) 
74/691 
(10.7) 
31/243 
(12.8) 
15/155 
(9.7) 
8/76 
(10.5) 
10/53 
(18.9) 
5/38 
(13.2) 
2/16 
(12.5) 
4/17 
(23.5) 
3/14 
(21.4) 
Nitrofurazone 90/728 
(12.4) 
65/701 
(9.3) 
21/257 
(8.2) 
14/153 
(9.2) 
12/86 
(14.0) 
8/43 
(18.6) 
0/28 
(0) 
4/18 
(22.2) 
3/22 
(13.6) 
1/6 
(16.7) 
PTFE control 81/721 
(11.2) 
79/704 
(11.2) 
33/232 
(14.2) 
21/149 
(14.1) 
11/78 
(14.1) 
12/53 
(22.6) 
8/42 
(19.0) 
6/28 
(21.4) 
4/18 
(22.2) 
1/12 
(8.3) 
Cell counts are n/N (%) where N = number of participants with catheter duration of specified number 
of days and n = number with episode of CAUTI within six weeks of randomization 
PTFE = polytetrafluoroethylene control, CAUTI = catheter-associated urinary tract infection 
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Web Extra Material 
 Table i: Hospitals and specialties recruiting to the trial 
 
Hospital Specialties recruiting Silver Alloy Nitrofurazone PTFE control 
 N =   2097 N = 2153 N =   2144 
Aberdeen Royal Infirmary  
Cardiothoracic, general surgery, 
vascular, obstetrics & gynaecology 
459(21.9) 430(20.0) 434(20.2) 
Royal Blackburn & Burnley General 
Hospitals 
Obstetrics & gynaecology 
33(1.6) 40(1.9) 36(1.7) 
Blackpool Victoria Hospital 
Cardiothoracic, obstetrics & 
gynaecology 
69(3.3) 64(3.0) 69(3.2) 
Bristol Royal Infirmary Cardiothoracic, general surgery 1(0.0) 3(0.1) 2(0.1) 
Edinburgh Royal Infirmary 
 
Obstetrics & gynaecology 
36(1.7) 42(2.0) 28(1.3) 
Guy’s Hospital, London 
 
Renal transplant 
72(3.4) 75(3.5) 81(3.8) 
Harrogate District Hospital 
 
Obstetrics & gynaecology 
3(0.1) 0(0.0) 1(0.0) 
Hillingdon Hospital 
General surgery, obstetrics & 
gynaecology 
60(2.9) 72(3.3) 66(3.1) 
Hinchingbrooke Hospital 
 
Orthopaedics 
20(1.0) 22(1.0) 14(0.7) 
Raigmore Hospital, Inverness Orthopaedics, general surgery 269(12.8) 270(12.5) 243(11.3) 
Liverpool Women’s Hospital 
 
Obstetrics & gynaecology 
46(2.2) 57(2.6) 45(2.1) 
Newcastle General Hospital Neurosurgery, general surgery 240(11.4) 250(11.6) 264(12.3) 
Freeman Hospital, Newcastle 
 
Cardiothoracic 
147(7.0) 155(7.2) 165(7.7) 
Royal Victoria Infirmary, Newcastle 
 
Obstetrics & gynaecology 
95(4.5) 95(4.4) 113(5.3) 
Norfolk and Norwich University 
Hospital 
Orthopaedics, obstetrics & 
gynaecology 
5(0.2) 14(0.7) 9(0.4) 
North Tyneside General Hospital 
General surgery, urology, 
obstetrics & gynaecology, medical 
ward, orthopaedics 
144(6.9) 156(7.2) 155(7.2) 
Nottingham City Hospital 
Orthopaedics, obstetrics & 
gynaecology 
47(2.2) 46(2.1) 51(2.4) 
Queen Alexandra Hospital, Portsmouth Obstetrics & gynaecology 43(2.1) 50(2.3) 51(2.4) 
Royal Preston Hospital 
 
Obstetrics & gynaecology 
37(1.8) 34(1.6) 36(1.7) 
Southampton General Hospital Cardiothoracic 187(8.9) 189(8.8) 178(8.3) 
Sunderland Royal Hospital 
 
Obstetrics & gynaecology 
16(0.8) 18(0.8) 29(1.4) 
Musgrove Park Hospital, Taunton General Surgery, orthopaedics 10(0.5) 8(0.4) 6(0.3) 
Torbay Hospital General Surgery, medical ward 22(1.0) 27(1.3) 26(1.2) 
Yeovil District Hospital 
General Surgery, obstetrics & 
gynaecology 
36(1.7) 36(1.7) 42(2.0) 
Cell values are n (%) of participants recruited and included in analysis.  PTFE = polytetrafluoroethylene  
 
 
Table ii: Participant recruitment according to specialty 
 
Specialty  
Silver alloy 
N =   2087 
Nitrofurazone 
N =   2146 
PTFE control 
N =  2141 
Medical 
 5 (<1) 3(<1) 4 (<1) 
Urology 
 45 (2) 44 (2) 56 (3) 
Cardiothoracic and vascular 
 567 (27) 580 (27) 567 (27) 
General surgery 
 194 (9) 202 (9) 220 (10) 
Obstetrics and gynaecology 
 705 (34) 732 (34) 737 (34) 
Orthopaedics 
 328 (16) 335 (16) 295 (14) 
Neurosurgery/Ear, nose and 
throat/Maxillofacial 243 (12) 250 (12) 262 (12) 
Cell values are n (%). PTFE = polytetrafluoroethylene 
